Analytical Data
-
Gene name
DEFa4
- Application
-
Alternative Names
DEFa4；DEF4；Defensin alpha 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12838
-
Expression Region
1-97aa
-
AA Sequence
MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
-
Molecular Weight
10.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFa4 is a member of the defensin family, which are small, cationic peptides that play a critical role in the innate immune response by exhibiting antimicrobial properties against a wide range of pathogens. The interest in DEFa4 has surged due to its potential therapeutic applications, particularly in the treatment of infections and inflammatory diseases. Research has shown that DEFa4 can disrupt bacterial membranes, inhibit viral replication, and modulate immune responses, making it a promising candidate for developing new antimicrobial agents. Furthermore, the recombinant production of DEFa4 allows for more extensive studies into its structure-function relationships, stability, and interaction with various pathogens. Advances in genetic engineering and protein purification techniques have facilitated the reliable production of this peptide, enabling scientists to explore its efficacy and safety in vivo. Additionally, understanding DEFa4's mechanisms of action may lead to the design of novel antibiotics in an era of increasing antibiotic resistance. As such, DEFa4 continues to be a focal point of research aimed at harnessing its antimicrobial properties and elucidating its potential roles in immune modulation, paving the way for innovative therapeutic strategies.
